News &amp; Updates

A recent trial presented at ACC.25 has demonstrated the efficacy of AZD0780 in reducing low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia, with a favourable safety and tolerability profile.

Novel PCSK9 inhibitor for high cholesterol passes phase II trial

Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?

Long-term treatment with tirzepatide results in improved renal function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, regardless of the absence or presence of chronic kidney disease (CKD), according to a post hoc analysis of the SUMMIT trial presented at ACC.25.

Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?

15 Apr 2025

TB vax primer augments BCG-induced immune response in bladder cancer patients

Initial results of the phase I RUTIVAC-1 study show the potential of two doses of a tuberculosis (TB) vaccine given after surgery but before standard BCG* treatment to boost immunity and reduce the odds of recurrence in patients with non-muscle-invasive bladder cancer (NMIBC).

TB vax primer augments BCG-induced immune response in bladder cancer patients

15 Apr 2025

Gradual adalimumab tapering minimizes uveitis recurrence in children

In children with noninfectious uveitis being treated with adalimumab, tapering speed appears to affect the risk of relapse, with a slow, gradual approach emerging as the optimal strategy, according to a multicentre retrospective cohort study.

Gradual adalimumab tapering minimizes uveitis recurrence in children

Oral semaglutide reduces CV risk in T2D patients

Once-daily treatment with oral semaglutide, a GLP-1* receptor agonist, significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), according to the SOUL** trial presented at ACC.25.

Oral semaglutide reduces CV risk in T2D patients

Shockwave therapy plus tadalafil beneficial to Asians with ED

14 Apr 2025 by

In the treatment of mild to moderate erectile dysfunction (ED), low-intensity extracorporeal shockwave therapy combined with tadalafil helps improve outcomes, according to the preliminary results of a study from China.

Shockwave therapy plus tadalafil beneficial to Asians with ED

14 Apr 2025

Does surgery plus SBRT increase ALP risk patients with spine metastases?

Separation surgery followed by conformal postoperative spine stereotactic body radiation therapy (S-SBRT) shows similar infield and adjacent level progression (ALP) when compared with SBRT alone in patients with spine metastases, reports a study.

Does surgery plus SBRT increase ALP risk patients with spine metastases?

Is it advisable to resume DOAC use 1 day after colorectal ESD?

14 Apr 2025 by

Resumption of direct oral anticoagulants (DOACs) a day after undergoing colorectal endoscopic submucosal dissection (ESD) results in fewer thromboembolic events without elevating the risk of delayed bleeding compared with 2 or 3 days after ESD, reports a study.

Is it advisable to resume DOAC use 1 day after colorectal ESD?

Surgery plus RT improves outcomes in cutaneous adnexal carcinoma

Surgical resection and adjuvant radiotherapy (RT) show effective control of cutaneous adnexal carcinoma (CAC), a rare skin cancer with no established treatment guidelines, while definitive RT does not, a study has found.

Surgery plus RT improves outcomes in cutaneous adnexal carcinoma

Nirmatrelvir-ritonavir for COVID-19 works in patients with advanced kidney dysfunction

Treatment with nirmatrelvir-ritonavir yields reductions in the risk of acute respiratory failure and pneumonia in COVID-19 patients with advanced kidney function, according to a retrospective matched cohort study.

Nirmatrelvir-ritonavir for COVID-19 works in patients with advanced kidney dysfunction